Following the news that 29 UK experimental cancer medicine centers (ECMCs) are set to share £47.5 million over the next five years to boost trials of personalized cancer therapies.

Thursday 19th January 2023

Kate Shaw, co-founder, and CEO of Innovative Trials, said: “Accelerating patient access to innovative medicines through clinical trials is our key mission at Innovative Trials, so I wholeheartedly welcome this news.

“Cancer is a devastating and complex disease that affects tens of thousands of people, including around 4,200 children and young people each year in the UK. With so many different types and sub-types of cancer, we need more personalized therapies to target cancer cells in very specific ways and help more people overcome the disease.

“Enabling ECMCs to conduct more trials by giving them this extra funding will not only help more people – children and adults alike – to receive these treatments faster through clinical studies, but will speed up the process of turning innovative lab research into clinical reality.”

The funding comes thanks to a partnership between Cancer Research UK, the National Institute for Health and Care Research (NIHR) and the Little Princess Trust.




For more information, please contact Laura Gibson at Presence Media at +44 7771 933609 or [email protected]

Notes to editors

About Innovative Trials

Innovative Trials is a leading global clinical trial patient recruitment and retention company. With over 10 years’ experience, Innovative Trials deploys “boots-on-the-ground” patient recruitment experts in over 70 countries, addressing individual sites’ unique recruitment and retention challenges in the local language. 

Innovative Trials has experience in over 25 therapeutic areas across 90+ conditions working with some of the biggest global pharmaceuticals, Clinical Research Organizations (CROs) and biotech companies.

Innovative Trials was founded in 2010 by Kate Shaw and Dave Watkins after identifying a growing need for clinical trial patient recruitment support.

For more information, visit